Syngeneic Studies

Cancer immunotherapies work with a patient's own immune system to increase native anti-tumor responses. In the development of these drugs, conventional patient-derived xenograft (PDX) models lack relevance due to the animals' immunocompromised status.

Syngeneic mouse models, however, consist of tumor tissues from the same genetic background as the given immuno-competent mouse strain. A syngeneic mouse model provides an effective approach for studying how cancer therapies perform in the presence of a functional immune system.

Advantages of Syngeneic Mice Studies at JAX

• Establish or confirm the synergistic response of your test article used in conjunction with checkpoint inhibitor reference compounds.
• Syngeneic tumor models from JAX have characterized response data for Anti PD-1 and Anti CTLA-4 checkpoint inhibitors.
• Work with the world leaders in preclinical immuno-oncology model development.